国产吉西他滨联合顺铂治疗晚期非小细胞肺癌的近期疗效观察

The Clinical Study of Gemcitabin Plus Cisplatin in the Treatment of patients Advanced Non-small Cell Lung Cancer

目的观察国产吉西他滨(泽菲)联合顺铂(DDP)治疗晚期非小细胞肺癌(NSCLC)的近期临床疗效及毒副作用。方法自2007年8月至2008年2月对病理学或细胞学证实的可评价疗效的晚期非小细胞肺癌(NSCLC)40例,治疗21～28天为一个周期,2～3周期后评价疗效和毒副反应。结果40例患者中,总有效率为42.5%,鳞癌组有效率为47.4%,腺癌组有效率为42.9%,鳞癌、腺癌组间差异无统计学意义(P>0.05)。毒副作用主要是骨髓抑制,其他毒副反应有恶心、呕吐、口腔炎、脱发、静脉炎、腹泻等,但发生率均较低。结论国产吉西他滨(泽菲)与顺铂(DDP)治疗晚期非小细胞肺癌(NSCLC),疗效好,毒副反应可以耐受。

Objective To observe the efficacy, toxicity of domestic Gemcitabin（Zefei） Combined with cisplatin regimen in advanced non-small-cell lung cancer. Methods From August 2007 to february 2008,19 cases squamous cell carcinoma and 21 cases adenocarcinoma of 40 cases of advanced non-small cell lung cancer were treated by chemotherapy of gemcitabin and cisplatin, and repeated every 21 - 28 days, then to evaluate the efficacy and toxicity. Results Among 40 cases the total effective power was 42. 5 %, the effective power of squamous cell carcinoma is 47.4% , and the effective power of adenocarcinoma is 42.9% , they have no differences （P 〉 0.05 ）. The major toxicity is bone marrow restrain, there are other toxicities including nansea/vomiting, stomatitis, triehomadesis, phlebitis, diarrhea etc,The morbidity is lower. Conclusion Gemeitabin and cisplatin regimen to advanced non-small-cell lung cancer has more satisfied efficacy, the toxicity is bearable.